213 related articles for article (PubMed ID: 32672528)
1. Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches.
Idris MO; Yekeen AA; Alakanse OS; Durojaye OA
J Biomol Struct Dyn; 2021 Sep; 39(15):5638-5656. PubMed ID: 32672528
[TBL] [Abstract][Full Text] [Related]
2. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
Abdizadeh R; Hadizadeh F; Abdizadeh T
J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
[TBL] [Abstract][Full Text] [Related]
4. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; Brás NF; Jha HC
J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
[TBL] [Abstract][Full Text] [Related]
5. Relaxed complex scheme and molecular dynamics simulation suggests small molecule inhibitor of human TMPRSS2 for combating COVID-19.
Vuai SAH; Ogedjo MM; Isaac O; Sahini MG; Swai HS; Shadrack DM
J Biomol Struct Dyn; 2022; 40(24):13925-13935. PubMed ID: 34751094
[TBL] [Abstract][Full Text] [Related]
6. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
Wang Y; Gao Q; Yao P; Yao Q; Zhang J
J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
[TBL] [Abstract][Full Text] [Related]
8. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
9. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
10. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
11. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
12. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
13. Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.
Tachoua W; Kabrine M; Mushtaq M; Selmi A; Ul-Haq Z
J Biomol Struct Dyn; 2023; 41(22):12908-12922. PubMed ID: 36709428
[TBL] [Abstract][Full Text] [Related]
14. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches.
Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S
J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693
[TBL] [Abstract][Full Text] [Related]
15. In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19.
Wang S; Fang X; Wang Y
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807455
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
18. An efficient eco-friendly, simple, and green synthesis of some new spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives as potential inhibitors of SARS-CoV-2 proteases: drug-likeness, pharmacophore, molecular docking, and DFT exploration.
El-Saghier AM; Enaili SS; Abdou A; Kadry AM
Mol Divers; 2024 Feb; 28(1):249-270. PubMed ID: 37946070
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation.
Daoud I; Mesli F; Melkemi N; Ghalem S; Salah T
J Biomol Struct Dyn; 2022; 40(23):12574-12591. PubMed ID: 34541995
[TBL] [Abstract][Full Text] [Related]
20. Identification, virtual screening and molecular dynamic analysis of novel TMPRSS2 inhibitors from natural compound database as potential entry-blocking agents in SARS-CoV-2 therapy.
Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK
Struct Chem; 2022; 33(5):1609-1617. PubMed ID: 35754942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
